BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Achieves Important Milestones in Fight against Advanced Breast Cancer
New, frozen formulation of ready-to-inject Bria-IMT increases potency, simplifies logistics and is expected to reduce cost-per-dose BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer Founder and Director Dr. Charles L. Wiseman will be a keynote speaker at the 10th Euro Breast Cancer Summit in Paris on March 21-22 Researchers at BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer, are noting significant advancements in clinical trials of the company’s lead cellular immunotherapy product, Bria-IMT, targeting advanced breast cancer.…